Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2006; 12(17): 2756-2761
Published online May 7, 2006. doi: 10.3748/wjg.v12.i17.2756
Published online May 7, 2006. doi: 10.3748/wjg.v12.i17.2756
Table 4 Comparison of quality of life scores before and after treatment (mean±SD)
| Status | Before treatment | After treatment | ||||
| Ecabet group(n = 115) | Cimetidine group(n = 121) | P | Ecabet group(n = 115) | Cimetidine group(n = 121) | P | |
| Eating status | 15.0 ± 4.6 | 14.8 ± 4.1 | NS | 15.6 ± 4.0 | 15.9 ± 3.5 | NS |
| Liveliness status | 10.4 ± 4.1 | 10.0 ± 4.0 | NS | 11.6 ± 3.6 | 11.3 ± 3.5 | NS |
| Psychological status | 18.5 ± 5.0 | 18.6 ± 4.5 | NS | 20.3 ± 4.4 | 20.4 ± 4.1 | NS |
| Role-functioning status | 20.5 ± 4.2 | 20.6 ± 4.2 | NS | 21.4 ± 3.9 | 21.0 ± 4.3 | NS |
- Citation: Lee JH, Kim JJ, Hahm KB, Lee DH, Kim N, Kim SK, Park JJ, Choi SR, Lee JH, Lee ST, Lee EH, Rhee JC. Efficacy and safety of ecabet sodium on functional dyspepsia: A prospective, double-blinded, randomized, multi-center controlled trial. World J Gastroenterol 2006; 12(17): 2756-2761
- URL: https://www.wjgnet.com/1007-9327/full/v12/i17/2756.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i17.2756